These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 9422559

  • 1. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
    Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander E, Black PM, Coleman CN.
    Int J Radiat Oncol Biol Phys; 1998 Jan 01; 40(1):65-70. PubMed ID: 9422559
    [Abstract] [Full Text] [Related]

  • 2. A phase I study of etanidazole and radiotherapy in malignant glioma.
    Riese NE, Loeffler JS, Wen P, Alexander E, Black PM, Coleman CN.
    Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):617-20. PubMed ID: 8005825
    [Abstract] [Full Text] [Related]

  • 3. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
    Prados MD, Scott CB, Rotman M, Rubin P, Murray K, Sause W, Asbell S, Comis R, Curran W, Nelson J, Davis RL, Levin VA, Lamborn K, Phillips TL.
    Int J Radiat Oncol Biol Phys; 1998 Feb 01; 40(3):653-9. PubMed ID: 9486616
    [Abstract] [Full Text] [Related]

  • 4. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
    Levin VA, Prados MR, Wara WM, Davis RL, Gutin PH, Phillips TL, Lamborn K, Wilson CB.
    Int J Radiat Oncol Biol Phys; 1995 Apr 30; 32(1):75-83. PubMed ID: 7721642
    [Abstract] [Full Text] [Related]

  • 5. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, Phillips TL, Larson DA.
    Int J Radiat Oncol Biol Phys; 2001 Jan 01; 49(1):71-7. PubMed ID: 11163499
    [Abstract] [Full Text] [Related]

  • 6. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
    Marcus KJ, Dutton SC, Barnes P, Coleman CN, Pomeroy SL, Goumnerova L, Billett AL, Kieran M, Tarbell NJ.
    Int J Radiat Oncol Biol Phys; 2003 Apr 01; 55(5):1182-5. PubMed ID: 12654425
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
    Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR, Meyers CA, Ictech SA, Chang E, Maor MH.
    Int J Radiat Oncol Biol Phys; 2002 May 01; 53(1):58-66. PubMed ID: 12007942
    [Abstract] [Full Text] [Related]

  • 8. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
    Prados MD, Scott C, Sandler H, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ.
    Int J Radiat Oncol Biol Phys; 1999 Dec 01; 45(5):1109-15. PubMed ID: 10613302
    [Abstract] [Full Text] [Related]

  • 9. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study.
    Jeremic B, Shibamoto Y, Grujicic D, Stojanovic M, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J.
    J Neurooncol; 2001 Jan 01; 51(2):133-41. PubMed ID: 11386410
    [Abstract] [Full Text] [Related]

  • 10. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
    Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1147-52. PubMed ID: 15001257
    [Abstract] [Full Text] [Related]

  • 11. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
    Prados MD, Larson DA, Lamborn K, McDermott MW, Sneed PK, Wara WM, Chang SM, Mack EE, Krouwer HG, Chandler KL, Warnick RE, Davis RL, Rabbitt JE, Malec M, Levin VA, Gutin PH, Phillips TL, Wilson CB.
    Int J Radiat Oncol Biol Phys; 1998 Jan 01; 40(1):57-63. PubMed ID: 9422558
    [Abstract] [Full Text] [Related]

  • 12. Interstitial iridium-192 implantation for malignant brain tumours. Part II: Clinical experience.
    Chun M, McKeough P, Wu A, Kasdon D, Heros D, Chang H.
    Br J Radiol; 1989 Feb 01; 62(734):158-62. PubMed ID: 2538197
    [Abstract] [Full Text] [Related]

  • 13. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
    Mizoe JE, Tsujii H, Hasegawa A, Yanagi T, Takagi R, Kamada T, Tsuji H, Takakura K, Organizing Committee of the Central Nervous System Tumor Working Group.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):390-6. PubMed ID: 17459607
    [Abstract] [Full Text] [Related]

  • 14. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma.
    Sullivan FJ, Herscher LL, Cook JA, Smith J, Steinberg SM, Epstein AH, Oldfield EH, Goffman TE, Kinsella TJ, Mitchell JB.
    Int J Radiat Oncol Biol Phys; 1994 Oct 15; 30(3):583-90. PubMed ID: 7928489
    [Abstract] [Full Text] [Related]

  • 15. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
    Groves MD, Maor MH, Meyers C, Kyritsis AP, Jaeckle KA, Yung WK, Sawaya RE, Hess K, Bruner JM, Peterson P, Levin VA.
    Int J Radiat Oncol Biol Phys; 1999 Aug 01; 45(1):127-35. PubMed ID: 10477016
    [Abstract] [Full Text] [Related]

  • 16. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
    Reulen HJ, Poepperl G, Goetz C, Gildehaus FJ, Schmidt M, Tatsch K, Pietsch T, Kraus T, Rachinger W.
    J Neurosurg; 2015 Sep 01; 123(3):760-70. PubMed ID: 26140493
    [Abstract] [Full Text] [Related]

  • 17. Radiation Therapy Oncology Group (RTOG) survival data on anaplastic astrocytomas of the brain: does a more aggressive form of treatment adversely impact survival?
    Laramore GE, Martz KL, Nelson JS, Griffin TW, Chang CH, Horton J.
    Int J Radiat Oncol Biol Phys; 1989 Dec 01; 17(6):1351-6. PubMed ID: 2689399
    [Abstract] [Full Text] [Related]

  • 18. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
    Nelson DF, Curran WJ, Scott C, Nelson JS, Weinstein AS, Ahmad K, Constine LS, Murray K, Powlis WD, Mohiuddin M.
    Int J Radiat Oncol Biol Phys; 1993 Jan 15; 25(2):193-207. PubMed ID: 8380567
    [Abstract] [Full Text] [Related]

  • 19. Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme.
    Krishnasamy S, Vokes EE, Dohrmann GJ, Mick R, Garcia JC, Kolker JD, Wollmann RL, Hekmatpanah J, Weichselbaum RR.
    Cancer Invest; 1995 Jan 15; 13(5):453-9. PubMed ID: 7552809
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.